

92470

Access DB# _____

SEARCH REQUEST FORM

Scientific and Technical Information Center

Requester's Full Name: BFRCH Examiner #: 5918 Date: 4/28/03
 Art Unit: 1624 Phone Number 30 84718 Serial Number: 09/035149
 Mail Box and Bldg/Room Location: 4D15 Results Format Preferred (circle): PAPER DISK E-MAIL 4E12

If more than one search is submitted, please prioritize searches in order of need.


Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: _____

Inventors (please provide full names): _____

Earliest Priority Filing Date: _____

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.



Note - 1-H/C is in case ~~████████~~ D6/H is altered

 STAFF USE ONLY

Type of Search

Vendors and cost where applicable

Searcher: _____	NA Sequence (#): _____	STN: _____
Searcher Phone #: _____	AA Sequence (#): _____	Dialog: _____
Searcher Location: _____	Structure (#): _____	Questel/Orbit: _____
Date Searcher Picked Up: <u>4/28/03</u>	Bibliographic: _____	Dr. Link: _____
Date Completed: <u>5/1/03</u>	Litigation: _____	Lexis/Nexis: _____
Searcher Prep & Review Time: <u>8</u>	Fulltext: _____	Sequence Systems: _____
Clerical Prep Time: _____	Patent Family: _____	WWW/Internet: _____
Online Time: _____	Other: _____	Other (specify): _____

=> d his

(FILE 'HOME' ENTERED AT 10:50:24 ON 01 MAY 2003)

FILE 'REGISTRY' ENTERED AT 10:50:33 ON 01 MAY 2003

L1 STR L***

L2 17 S L1

L3 STR L1

L4 STR L***

L5 1 S L3 NOT L4

L6 10 S L3 NOT L4 FULL *10 compds, only 2 appear in lit.*
- see d one stat for structures

FILE 'HCAPLUS' ENTERED AT 12:43:33 ON 01 MAY 2003

L7 2 S L6 *2 cts from CR Plus*


FILE 'CAOLD' ENTERED AT 12:46:33 ON 01 MAY 2003

L8 0 S L7 *0 cts from CA Old*

* List of 10 compds attached

=> d que stat 17

L3 STR



VAR G1=C/H

REP G2=(1-3) C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

L4 STR



VAR G1=C/H

REP G2=(1-3) C

NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

ECOUNT IS M1-X5 C AT 19

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE

L6 10 SEA FILE=REGISTRY SSS FUL L3 NOT L4


L7 2 SEA FILE=HCAPLUS ABB=ON L6

=> d ibib abs hitstr 17 1-2

L7 ANSWER 1 OF 2 HCPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:676018 HCPLUS
DOCUMENT NUMBER: 137:216824
TITLE: Preparation of xanthine derivatives as dipeptidylpeptidase-IV inhibitors
INVENTOR(S): Himmelsbach, Frank; Mark, Michael; Eckhardt, Matthias;
Langkopf, Elke; Maier, Roland; Lotz, Ralf
PATENT ASSIGNEE(S): Boehringer Ingelheim Pharma K.-G., Germany
SOURCE: PCT Int. Appl., 373 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002068420	A1	20020906	WO 2002-EP1820	20020221
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10109021	A1	20020905	DE 2001-10109021	20010224
DE 10117803	A1	20021024	DE 2001-10117803	20010410
DE 10140345	A1	20030227	DE 2001-10140345	20010817
PRIORITY APPLN. INFO.:			DE 2001-10109021 A	20010224
			DE 2001-10117803 A	20010410
			DE 2001-10140345 A	20010817
			DE 2002-10203486 A	20020130

OTHER SOURCE(S): MARPAT 137:216824
GI




AB Xanthine derivs. of formula I [R1, R2 = H, alkyl, alkenyl, etc.; R3 = alkyl, arylalkyl, etc.; R4 = heterocyclyl, cycloalkyl, aminoalkyl, etc.] are prep'd. which exhibit an inhibitory effect on the activity of the dipeptidylpeptidase-IV enzyme. Pharmaceutical comps. contg. I are described. Thus, II was prep'd. and had an IC₅₀ of 22 nM against dipeptidylpeptidase-IV.

IT 454706-71-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of xanthine derivs. as dipeptidylpeptidase-IV inhibitors)
 RN 454706-71-9 HCPLUS
 CN 1H-Purine-2,6-dione, 7-(2,3-dimethyl-2-butenyl)-3,7-dihydro-1,3-dimethyl-8-(1-piperazinyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 2 HCPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1987:95577 HCPLUS
 DOCUMENT NUMBER: 106:95577
 TITLE: Synthesis and biological activity of 3-methyl, 7- or 8-alkyl-, 7,8-dialkyl, heterocyclic, and cyclohexylaminoxanthines
 AUTHOR(S): Romanenko, N. I.; Fedulova, I. V.; Primenko, B. O.; Orestenko, L. P.
 CORPORATE SOURCE: Zaporozh. Med. Inst., Zaporozhe, USSR
 SOURCE: Farmatsevtichniy Zhurnal (Kiev) (1986), (5), 41-4
 CODEN: FRZKAP; ISSN: 0367-3057
 DOCUMENT TYPE: Journal
 LANGUAGE: Ukrainian
 OTHER SOURCE(S): CASREACT 106:95577
 GI



AB Seventeen title compds. (I; R1 = heptyl, nonyl, or CH₂CH:C(Cl)Me; R2 = NMe₂, NEt₂, piperidino, cyclohexylamino, NHCH₂Ph, piperazino, morpholino, NHNH₂, N(CH₂CH₂OH)₂, etc.) were prep'd. by reacting the K salt of 8-bromo-3-methylxanthine with appropriate alkyl halides followed by condensation with appropriate primary or secondary amines. Toxicity studies in mice showed I to be less toxic than aminazine. Most I exhibited diuretic activity in rats, and some exhibited analeptic activity as well. Many I exhibited antimicrobial activity in vitro against both bacteria and fungi. The most active diuretics contained morpholino,

piperidino, or N-benzyl groups at the 8-position.

IT 106939-21-3P

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(prepn. and pharmacol. of, structure in relation to)

RN 106939-21-3 HCAPLUS

CN 1H-Purine-2,6-dione, 7-heptyl-3,7-dihydro-3-methyl-8-(1-piperazinyl)-
(9CI) (CA INDEX NAME)

